Table 4.

Univariate and multivariate predictors of early treatment discontinuation due to adverse event(s)

	All patients (n = 160)
	Univariate*		Multivariate†
Covariate	OR (95% CI)	P-value	OR (95% CI)	P-value
Decompensated cirrhosis (CP ≥6)	2.06 (0.93–4.60)	0.08	3.08 (1.28–7.42)	0.01
Race/ethnicity
White, nonhispanic	Reference	Reference	–	–
Hispanic	2.04 (0.74–5.61)	0.17
Black	3.20 (0.79–12.99)	0.10
Asian	2.67 (0.58–12.25)	0.21
Other	4.00 (0.61–25.96)	0.15
Genotype 1a (vs. 1b or other)	1.94 (0.83–4.53)	0.13	–	–
Albumin start treatment, per 1 g/dL	0.58 (0.28–1.17)	0.13	–	–
Creatinine start treatment, per 1 mg/dL	1.30 (0.89–1.92)	0.18	–	–
MELD start treatment, per 1	1.09 (0.96–1.24)	0.17	–	–

CP, Child-Pugh; MELD, model for end-stage liver disease.

^*Univariate results of variables with P < 0.20. Univariate analysis for every variable examined is presented in Table S3 [age, gender, race/ethnic group, HCV genotype 1a (vs. 1b or other), previous null or partial response to Peg-IFN/RBV treatment (vs. treatment naïve or relapsers to peg-IFN/RBV treatment), IL28B genotype CC (vs. CT/TT), baseline laboratory indices (bilirubin, creatinine, INR, albumin and platelet count), baseline MELD, baseline mildly decompensated cirrhosis CP ≥6 (vs. CP = 5), use of telaprevir (vs. boceprevir), baseline HCV viral load and presence of varices].

^†Adjusted for centre effect.